会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • 6-(1-hydroxyethyl)-2-carbamimidoyl-pen-2-em-3-carboxylic acids
    • 6-(1-羟基乙基)-2-氨甲脒基 - 二氧戊环-3-羧酸
    • US4650794A
    • 1987-03-17
    • US373088
    • 1982-04-29
    • Burton G. ChristensenFrank P. DiNinnoWilliam J. LeanzaRonald W. Ratcliffe
    • Burton G. ChristensenFrank P. DiNinnoWilliam J. LeanzaRonald W. Ratcliffe
    • C07D499/88C07D499/00A61K31/425
    • C07D499/88
    • Disclosed are 6-(1-hydroxyethyl)-2-carbamimidoyl-pen-2-em-3-carboxylic acids (I) having the representative structure: ##STR1## wherein: A is a direct, single bond connecting the indicated S and C atoms, or A is a cyclic or acyclic connecting group selected, inter alia, from alkyl, cycloalkyl, aryl, heteroaryl, heteroalkyl; R.sup.1 and R.sup.2, which define the carbamimidoyl function, are, inter alia, independently selected from hydrogen, alkyl, aryl, alkoxy, amino; additionally, said carbamimidoyl is characterized by cyclic structures achieved by the joinder of the two nitrogen atoms via their substituents and by their joinder to connecting group A; additionally, "carbamimidiums" are disclosed by quaternization of one of the nitrogen atoms of said carbamimidoyl. Such compounds as well as their pharmaceutically acceptable salt, ester and amide derivatives are useful as antibiotics. Also disclosed are processes for the preparation of such compounds; pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.
    • 公开了具有以下代表性结构的6-(1-羟基乙基)-2-氨基甲脒基 - 二-2-甲基-3-羧酸(I):其中:A是连接所指示的S和 C原子或A是环状或无环连接基团,特别是选自烷基,环烷基,芳基,杂芳基,杂烷基; 定义氨基甲酰基官能团的R 1和R 2尤其独立地选自氢,烷基,芳基,烷氧基,氨基; 另外,所述的氨基甲脒基的特征在于通过两个氮原子通过它们的取代基并通过它们与连接基团A的连接而实现的环状结构; 此外,“氨基甲酰胺”通过所述氨甲脒基的氮原子之一的季铵化来公开。 这些化合物及其药学上可接受的盐,酯和酰胺衍生物可用作抗生素。 还公开了制备这些化合物的方法; 包含这些化合物的药物组合物; 和治疗方法,包括当指出抗生素效应时施用这些化合物和组合物。
    • 4. 发明授权
    • 2-unsaturated alkylthio-pen-2-em-3-carboxylic acids
    • 2-不饱和烷硫基 - 笔-2-烯-3-羧酸
    • US4675317A
    • 1987-06-23
    • US460728
    • 1983-01-25
    • Frank P. DiNinnoWilliam J. LeanzaRonald W. RatcliffeDavid A. Muthard
    • Frank P. DiNinnoWilliam J. LeanzaRonald W. RatcliffeDavid A. Muthard
    • C07D205/09C07D205/095C07D499/88C07F7/18C07D499/00A61K31/425
    • C07D499/88C07D205/09C07D205/095C07F7/186
    • Disclosed are 6- and 6,6-disubstituted-2-substituted thio-pen-2-em-3-carboxylic acids of the following structure: ##STR1## wherein: R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are independently selected from: hydrogen; substituted and unsubstituted: alkyl, cycloalkyl, halo, alkoxyl, alkenyl, aralkyl, aryl, heterocyclyl, heteroaryl, and heterocyclylalkyl; W is an electron withdrawing group, and, for example, is selected from: --COR.sup.5, --CN, SO.sub.2 C.sub.6 H.sub.5 ; R.sup.5 is hydrogen; substituted and unsubstituted: alkyl, aryl, aralkyl, heteroaryl, heterocyclyl, or heterocyclylalkyl; or R.sup.5 may be --OR.sup.6, --NR.sup.7 R.sup.8, and --SR.sup.9 ; wherein R.sup.6 is H; substituted and unsubstituted: alkyl, alkenyl, or a group which defines --CO.sub.2 R.sup.6 as a pharmaceutically acceptable ester wherein R.sup.6 is, for example, phthalidyl, or 5-methyl-2-oxo-1,3-dioxolen-4-ylmethyl; R.sup.7 and R.sup.8 are independently selected from: hydrogen; substituted and unsubstituted: alkyl, aralkyl, aryl, heterocyclyl, and heterocyclylalkyl; R.sup.9 is substituted and unsubstituted: alkyl, aralkyl, aryl, heterocyclyl, and heterocyclyclalkyl; R.sup.3 may also be W; n is 0 or 1; when the unsaturated moiety attached to the exocyclic sulfur atom is acetylenic, then R.sup.3 and R.sup.4 are nonexistent and W is as previously defined. Such compounds I are new and they and their pharmaceutically acceptable salt and ester derivatives are useful as antibiotics.
    • 公开了具有以下结构的6-和6,6-二取代-2-取代的硫代 - 笔 - 2-em-3-羧酸:其中:R1,R2,R3和R4独立地选自: 氢; 烷基,环烷基,卤素,烷氧基,烯基,芳烷基,芳基,杂环基,杂芳基和杂环基烷基; W是吸电子基团,例如,选自:-COR 5,-CN,SO 2 C 6 H 5; R5是氢; 取代和未取代的:烷基,芳基,芳烷基,杂芳基,杂环基或杂环基烷基; 或者R 5可以是-OR 6,-NR 7 R 8和-SR 9; 其中R6是H; 取代和未取代的:烷基,烯基或定义-CO 2 R 6作为药学上可接受的酯的基团,其中R 6是例如酞基或5-甲基-2-氧代-1,3-二氧杂环戊烯-4-基甲基; R7和R8独立地选自:氢; 取代和未取代的:烷基,芳烷基,芳基,杂环基和杂环基烷基; R9是取代和未取代的:烷基,芳烷基,芳基,杂环基和杂环烷基; R3也可以是W; n为0或1; 当连接到环外硫原子上的不饱和部分是炔属时,则R3和R4不存在,W如前所定义。 这些化合物I是新的,它们及其药学上可接受的盐和酯衍生物可用作抗生素。
    • 5. 发明授权
    • Substituted N-methylene derivatives of thienamycin
    • 噻吩霉素的取代的N-亚甲基衍生物
    • US4311704A
    • 1982-01-19
    • US159573
    • 1980-06-16
    • Burton G. ChristensenWilliam J. LeanzaDavid H. ShihKenneth J. Wildonger
    • Burton G. ChristensenWilliam J. LeanzaDavid H. ShihKenneth J. Wildonger
    • C07D477/20C07D487/04A61K31/40A61K31/425A61K31/44
    • C07D477/20
    • Disclosed are substituted N-methylene derivatives of thienamycin having the formula: ##STR1## wherein: (1.) X.dbd.--NR.sup.1 R.sup.2, and Y.dbd.--R'--N.dbd.CRNR.sup.1 R.sup.2, and(2.) X.dbd.R, and Y.dbd.--NR.sup.1 R'N.dbd.CRNR.sup.1 R.sup.2 ; andwherein: R is, inter alia, hydrogen, NH.sub.2, --NHR.sup.1, --NR.sup.1 R.sup.2, R.sup.1 and R.sup.2 ; R.sup.1 and R.sup.2 are independently selected from: hydrogen, substituted, or unsubstituted: alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclyl, and heterocyclylalkyl; R' is --(CH.sub.2).sub.n.sup.-, n is 1-6, or --(CH.sub.2).sub.m --Q--(CH.sub.2).sub.p.sup.-, m, n.dbd.1-3 and Q is O, S or R' is a carbocyclic or heterocyclic ring. Such compounds and their pharmaceutically acceptable salt, ether, ester and amide derivatives are useful as antibiotics. Also disclosed are processes for the preparation of such compounds, pharmaceutical compositions comprising such compounds; and methods of treatment comprising administering such compounds and compositions when an antibiotic effect is indicated.
    • 公开了具有下式的噻吩霉素的取代的N-亚甲基衍生物:其中:(1)X = -NR 1 R 2,Y = -R'-N = CRNR 1 R 2,和(2)X = R,Y = -NR1R'N = CRNR1R2; 并且其中:R特别是氢,NH 2,-NHR 1,-NR 1 R 2,R 1和R 2; R 1和R 2独立地选自:氢,取代或未取代的:烷基,烯基,炔基,环烷基,环烷基烷基,芳基,芳烷基,杂芳基,杂芳烷基,杂环基和杂环基烷基; R'为 - (CH 2)n - ,n为1-6或 - (CH 2)m Q-(CH 2)p - ,m,n = 1-3,Q为O,S或R'为碳环或杂环 环。 这些化合物及其药学上可接受的盐,醚,酯和酰胺衍生物可用作抗生素。 还公开了制备这些化合物的方法,包含这些化合物的药物组合物; 和治疗方法,包括当指出抗生素效应时施用这些化合物和组合物。
    • 9. 发明授权
    • Process for preparing substituted 2-thioxopenams and 2-substituted
thiopenems
    • 制备取代的2-硫代戊二酸和2-取代的硫代青霉烯的方法
    • US4610823A
    • 1986-09-09
    • US460729
    • 1983-01-25
    • Frank P. DiNinnoWilliam J. LeanzaRonald W. Ratcliffe
    • Frank P. DiNinnoWilliam J. LeanzaRonald W. Ratcliffe
    • C07D205/08A61K31/397A61K31/425A61K31/43A61P31/04C07D205/09C07D205/095C07D499/04C07D499/42C07D499/44C07D499/88C07D499/897C07F1/10C07F3/14C07F5/00C07F7/18
    • C07D205/09C07D205/095C07D499/88C07F7/1804Y02P20/55
    • Disclosed is a synthesis for preparing substituted 2-thioxopenams which are useful in the synthesis of penem antibiotics 7 which may be conducted in an enantiospecific manner; said process proceeds from azetidinone 1 via the azetidinone acetic ester 2, the 4-metallothiozetidinone 3, and the 4-dithiocarbonylazetidinone 4 to the substituted 2-thioxopenam 5: ##STR1## wherein: R.sup.6 and R.sup.7 are independently selected from: hydrogen; R.sup.6 NH-- (R.sup.6 is acyl or H); substituted and unsubstituted: alkyl, alkenyl, alkynyl, aryl, heterocyclyl, heteroaryl, cycloalkyl, and cycloalkenyl; wherein said substituents are, inter alia: halo (chloro, bromo, fluoro, iodo), hydroxyl, cyano, carboxyl, amino, and the above-recited values for R.sup.6 and R.sup.7 ; in functional terms,R.sup.2 is a group which potentially forms a stable carbonium ion, for example: trityl (--C(C.sub.6 H.sub.5).sub.3),bis(p-methoxyphenyl)methyl, ##STR2## --2,4-dimethoxybenzyl, ##STR3## 2-(diphenyl)isopropyl, ##STR4## and the like; M is a thiophilic metal such as silver, thallium, mercury, or the like;and R.sup.1 is a protecting group such as allyl, p-nitrobenzyl or a biologically removable group (pharmaceutically acceptable ester moiety), for example: pivaloyloxymethyl, pivoloyloxyethyl, ethoxycarbonyloxymethyl, phthalidyl (5-methyl-2-oxo-1,3-dioxolen-4-yl)-; and X is a methyl leaving group such as phenoxy, p-chlorophenoxy, p-nitrophenoxy, phenylthio, alkylthio, alkoxy, chloro, or the like.R.sup.8 is inter alia, substituted and unsubstituted alkyl; the final penem products 7 are known, and their various embodiments are included by this definition.
    • 公开了用于制备可以以对映体特异性方式进行的penem抗生素7的合成的用于制备取代的2-硫代青霉烯的合成物; 所述方法从氮杂环丁酮1经由氮杂环丁酮乙酸酯2,4-金属硫代环丁酮3和4-二硫代羰基氮杂环丁酮4进行到取代的2-硫青霉素5,其中:R6 和R 7独立地选自:氢; R6NH-(R6是酰基或H); 取代和未取代的:烷基,烯基,炔基,芳基,杂环基,杂芳基,环烷基和环烯基; 其中所述取代基特别是:卤素(氯,溴,氟,碘),羟基,氰基,羧基,氨基,以及R6和R7的上述值; 在功能上,R2是潜在形成稳定的碳鎓离子的基团,例如:三苯甲基(-C(C 6 H 5)3),双(对甲氧基苯基)甲基,2,4-二甲氧基苄基, 2-(二苯基)异丙基,等等; M是硫醇类金属如银,铊,汞等; R1为保护基团,例如烯丙基,对硝基苄基或生物可除去基团(药学上可接受的酯部分),例如:新戊酰氧基甲基,桥联合氧基乙基,乙氧基羰氧基甲基,邻苯二甲酰基(5-甲基-2-氧代-1,3-二氧杂环戊烯 - 吡啶-4-基) - ; X为甲基离去基团,例如苯氧基,对氯苯氧基,对硝基苯氧基,苯硫基,烷硫基,烷氧基,氯等。 R8尤其是取代和未取代的烷基; 最终的penem产品7是已知的,并且它们的各种实施例被该定义包括。